{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:12:35Z","timestamp":1785420755872,"version":"3.56.0"},"reference-count":12,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI179827"],"award-info":[{"award-number":["1R01AI179827"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["KANT23G0"],"award-info":[{"award-number":["KANT23G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Patients with cystic fibrosis have dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR), and this predisposes them to nontuberculous mycobacteria (NTM), including\n                      <jats:italic toggle=\"yes\">Mycobacterium abscessus<\/jats:italic>\n                      (MAB)\n                      <jats:italic toggle=\"yes\">,<\/jats:italic>\n                      infection. We found that one of the CFTR modulators, ivacaftor, kills MAB in a concentration-dependent manner, with killing efficacy comparable to amikacin and imipenem, drugs in guideline-based regimens. Using clinical isolates of MAB, amikacin 1\/4\u00d7 MIC concentration combined with ivacaftor killed 2.67 log\n                      <jats:sub>10<\/jats:sub>\n                      CFU\/mL MAB.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00030-25","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T09:00:50Z","timestamp":1747299650000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Ivacaftor affects the susceptibility of standard-of-care drugs used to treat\n                    <i>Mycobacterium abscessus<\/i>\n                    lung disease"],"prefix":"10.1128","volume":"69","author":[{"given":"Avneesh","family":"Shrivastava","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4601-5673","authenticated-orcid":true,"given":"Sanjay","family":"Singh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunavanthi D.","family":"Boorgula","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo-Amaro","family":"Galvez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Section of Pulmonary and Critical Care, School of Medicine, University of Texas at Tyler","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8786-8851","authenticated-orcid":true,"given":"Shashikant","family":"Srivastava","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler","place":["Tyler, USA"]},{"id":[{"id":"https:\/\/ror.org\/01sps7q28","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Cellular and Molecular Biology, University of Texas Health Science Centre at Tyler","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"No Author Listed. 2021. Cystic fibrosis foundation patient registry. Annual data report 2020. Cystic Fibrosis Foundation"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201909-1874ST"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01206-17"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23825"},{"key":"e_1_3_3_6_2","unstructured":"No Author Listed. 2019. TRIKAFTA (elexacaftor tezacaftor and ivacaftor tablets; ivacaftor tablets) co-packaged for oral use"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25637"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.05.003"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00724-2021"},{"key":"e_1_3_3_10_2","series-title":"CLSI Standard M24","volume-title":"Susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes","year":"2018","unstructured":"CLSI. 2018. Susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes. 3rd ed. CLSI Standard M24","edition":"3"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.02.004"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04083-22"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/428051"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00030-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00030-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T09:01:14Z","timestamp":1749027674000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00030-25"}},"subtitle":[],"editor":[{"given":"Sean","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"alternative-id":["10.1128\/aac.00030-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.00030-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"2025-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00030-25"}}